IBDEI1MY ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29044,1,3,0)
 ;;=3^Anxiety
 ;;^UTILITY(U,$J,358.3,29044,1,4,0)
 ;;=4^300.00
 ;;^UTILITY(U,$J,358.3,29044,2)
 ;;=^9200
 ;;^UTILITY(U,$J,358.3,29045,0)
 ;;=716.90^^171^1854^8
 ;;^UTILITY(U,$J,358.3,29045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29045,1,3,0)
 ;;=3^Arthropathy NOS
 ;;^UTILITY(U,$J,358.3,29045,1,4,0)
 ;;=4^716.90
 ;;^UTILITY(U,$J,358.3,29045,2)
 ;;=^66343
 ;;^UTILITY(U,$J,358.3,29046,0)
 ;;=314.00^^171^1854^9
 ;;^UTILITY(U,$J,358.3,29046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29046,1,3,0)
 ;;=3^Attention Defic Nonhyperactive
 ;;^UTILITY(U,$J,358.3,29046,1,4,0)
 ;;=4^314.00
 ;;^UTILITY(U,$J,358.3,29046,2)
 ;;=^268351
 ;;^UTILITY(U,$J,358.3,29047,0)
 ;;=496.^^171^1854^17
 ;;^UTILITY(U,$J,358.3,29047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29047,1,3,0)
 ;;=3^Chr Airway Obstruction NEC
 ;;^UTILITY(U,$J,358.3,29047,1,4,0)
 ;;=4^496.
 ;;^UTILITY(U,$J,358.3,29047,2)
 ;;=^24355
 ;;^UTILITY(U,$J,358.3,29048,0)
 ;;=585.3^^171^1854^21
 ;;^UTILITY(U,$J,358.3,29048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29048,1,3,0)
 ;;=3^Chr Kidney Disease,Stage III
 ;;^UTILITY(U,$J,358.3,29048,1,4,0)
 ;;=4^585.3
 ;;^UTILITY(U,$J,358.3,29048,2)
 ;;=^332809
 ;;^UTILITY(U,$J,358.3,29049,0)
 ;;=585.4^^171^1854^22
 ;;^UTILITY(U,$J,358.3,29049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29049,1,3,0)
 ;;=3^Chr Kidney Disease,Stage IV
 ;;^UTILITY(U,$J,358.3,29049,1,4,0)
 ;;=4^585.4
 ;;^UTILITY(U,$J,358.3,29049,2)
 ;;=^332810
 ;;^UTILITY(U,$J,358.3,29050,0)
 ;;=585.1^^171^1854^19
 ;;^UTILITY(U,$J,358.3,29050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29050,1,3,0)
 ;;=3^Chr Kidney Disease,Stage I
 ;;^UTILITY(U,$J,358.3,29050,1,4,0)
 ;;=4^585.1
 ;;^UTILITY(U,$J,358.3,29050,2)
 ;;=^332807
 ;;^UTILITY(U,$J,358.3,29051,0)
 ;;=585.2^^171^1854^20
 ;;^UTILITY(U,$J,358.3,29051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29051,1,3,0)
 ;;=3^Chr Kidney Disease,Stage II
 ;;^UTILITY(U,$J,358.3,29051,1,4,0)
 ;;=4^585.2
 ;;^UTILITY(U,$J,358.3,29051,2)
 ;;=^332808
 ;;^UTILITY(U,$J,358.3,29052,0)
 ;;=585.5^^171^1854^23
 ;;^UTILITY(U,$J,358.3,29052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29052,1,3,0)
 ;;=3^Chr Kidney Disease,Stage V
 ;;^UTILITY(U,$J,358.3,29052,1,4,0)
 ;;=4^585.5
 ;;^UTILITY(U,$J,358.3,29052,2)
 ;;=^332811
 ;;^UTILITY(U,$J,358.3,29053,0)
 ;;=585.9^^171^1854^18
 ;;^UTILITY(U,$J,358.3,29053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29053,1,3,0)
 ;;=3^Chr Kidney Disease NOS
 ;;^UTILITY(U,$J,358.3,29053,1,4,0)
 ;;=4^585.9
 ;;^UTILITY(U,$J,358.3,29053,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,29054,0)
 ;;=428.0^^171^1854^26
 ;;^UTILITY(U,$J,358.3,29054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29054,1,3,0)
 ;;=3^Congestive Heart Failure,Unspec
 ;;^UTILITY(U,$J,358.3,29054,1,4,0)
 ;;=4^428.0
 ;;^UTILITY(U,$J,358.3,29054,2)
 ;;=^54758
 ;;^UTILITY(U,$J,358.3,29055,0)
 ;;=414.01^^171^1854^27
 ;;^UTILITY(U,$J,358.3,29055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29055,1,3,0)
 ;;=3^Cor Atheroscl Native Vessel
 ;;^UTILITY(U,$J,358.3,29055,1,4,0)
 ;;=4^414.01
 ;;^UTILITY(U,$J,358.3,29055,2)
 ;;=^303281
 ;;^UTILITY(U,$J,358.3,29056,0)
 ;;=585.6^^171^1854^35
 ;;^UTILITY(U,$J,358.3,29056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29056,1,3,0)
 ;;=3^ESRD
 ;;^UTILITY(U,$J,358.3,29056,1,4,0)
 ;;=4^585.6
 ;;^UTILITY(U,$J,358.3,29056,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,29057,0)
 ;;=401.9^^171^1854^41
 ;;^UTILITY(U,$J,358.3,29057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29057,1,3,0)
 ;;=3^Hypertension
 ;;^UTILITY(U,$J,358.3,29057,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,29057,2)
 ;;=^186630
 ;;
 ;;$END ROU IBDEI1MY
